Omkar Spl.Chem.

- No major new fundraising through debt or equity is planned currently. - The company does not anticipate big CAPEX in the next two years except for minor debottlenecking and capitalizing existing work-in-progress (around Rs. 10 to 12 crores). - Any significant fundraising may only occur if an acquisition opportunity arises which is remunerative to the company. - Routine business growth will be supported by existing capacities and current financial resources without additional major debt or equity infusion.

- No major CAPEX planned in the next two years. - Only debottlenecking CAPEX and capital work-in-progress capitalization expected, amounting to around Rs. 10 to 12 crores. - Existing CAPEX is sufficient to support the current growth rate for the next two years. - New CAPEX might arise only in case of an acquisition or an unforeseen remunerative opportunity. - Company is considering acquisition in the formulations space but nothing concrete or on the table currently.

- The company is guiding for around 25% year-on-year growth in Pharma Intermediates as well as APIs on a consolidated basis. (Page 11) - The new API manufacturing Unit #5 in Chiplun is expected to start production in Q1 FY17 with gradual scale-up, reaching good utilization and sales from Q2 FY17 onwards, focusing on Vitamin C and Folic Acid with healthy margins and significant growth opportunities. (Pages 6,11) - About 20% to 25% of overall revenue is projected to come from Iodine Derivatives over the next two years, though the company is defocusing this segment due to lower margins. (Page 10) - The focus will be more on Specialty Intermediates, Resolving agents, and Veterinary APIs which are expected to show steep growth and better EBITDA margins. (Page 10) - The business model aims to maintain consistent EBITDA margins of around 18-19% despite raw material and forex fluctuations. (Page 6)

- Omkar Speciality Chemicals Ltd expects around 25% year-on-year growth in Pharma Intermediates and APIs (consolidated across segments). - EBITDA margins are consistently expected around 18-19%, with some segments like Vitamin C projected at 18-20%. - The new API manufacturing Unit #5 at Chiplun (starting Q1 FY17) will gradually scale up, contributing positively to sales and profits from Q2 FY17 onwards. - Focus is shifting towards higher margin Specialty Intermediates and APIs, reducing reliance on low-margin Iodine derivatives, which will constitute 20-25% of revenues in the next two years. - Working capital and operational efficiencies are improving, supporting better cash flows and margins. - No major CAPEX planned, barring acquisitions; expected small CAPEX (~Rs. 10-12 crores) to enhance current capacity. - Stable EBITDA and profit growth expected despite market volatilities like forex and raw material cost fluctuations.

- Omkar Speciality Chemicals does not maintain a traditional order book. - They operate on quarterly forecasts provided by their customers. - Orders flow continuously based on these forecasts. - The quarterly forecast is usually accurate with only a 10-15% variance. - Customers are mainly reputed MNCs like Glaxo, Gilead Life, Abbott, Johnson & Johnson, and BASF. - The forecasts provide guidance on expected sales volumes for the quarter. - This system gives the company confidence in projecting business for their Intermediates segment. - For APIs, demand is driven by customer product development and launch timelines. - The plant's first phase utilization and orders are expected to scale up gradually after commissioning in Q1 FY17.